Private Equity

RA Capital's major investment extends Karyopharm's runway, but future funding is now directly tied to the outcome of its pivotal endometrial cancer trial.

Goldman Sachs' strategic investment extends GeoWealth's Series C, signaling a major push to dominate the future of customized wealth management technology.

A new biotech spins out with a novel drug class aiming to provide healthier, more durable weight loss and combat cancer-related wasting syndrome.

Nearly a century old, NPF Investment Advisors launches an actively managed ETF, aiming to deliver tax efficiency and long-term growth to a new generation.

UK's Abselion opens a US base in Cambridge, MA, aiming to disrupt biologics R&D with its rapid Amperia protein quantification system.

With $336M in the bank and three autoimmune drugs advancing, Jade Biosciences lays out a fast-paced timeline for key clinical milestones in 2026 and 2027.

Industry veteran Louise Baker is named Managing Director of TricorBraun ANZ, a strategic move to unify recent acquisitions and drive growth in the region.

A new MMA league is letting fans and fighters buy in. With veteran leaders and a $5M equity raise, can the Global Fight League disrupt the octagon?

Montréal startup JetScale AI lands an oversubscribed seed round for its AI platform that slashes cloud spending and energy waste in just minutes.

Energy firm Prevalon and crypto bank Anchorage Digital add Strategy's high-yield STRC to their treasuries, marking a key step for institutional adoption.

Insurance giant Kuvare Holdings fires back at inaccurate reports, clarifying its independent oversight in a complex asset management deal with Blue Owl.

The Raine Group hires Credit Suisse veteran Anthony Kontoleon, signaling a major push to dominate TMT advisory ahead of an anticipated tech boom.

Amidst a volatile stock history, GT Biopharma aims to secure vital funding for its innovative NK cell therapy pipeline at a key Toronto conference.

As Pasithea Therapeutics heads to a key investor conference, all eyes are on its lead drug, PAS-004, and its potential to treat rare and complex diseases.

The major CRO acquisition deepens Worldwide's oncology and FSP capabilities, signaling a strategic move in the consolidating clinical research market.

Align Partners launches a major governance overhaul campaign at Dentium, aiming to fix the 'Korea discount' and unlock value at the undervalued market leader.

Bain Capital and Goldman Sachs finance Truelink's acquisition of SouthernCarlson, signaling private credit's growing power in middle-market deals.

As Churchill Capital XI's shares and warrants begin separate trading, what does this mean for investors and the hunt for Michael Klein's next big deal?

Following its majority stake acquisition from ExxonMobil, Canadian firm North Atlantic details its offer to fully control a key French refiner.

RedBird Capital Partners cements its control over AC Milan with a major refinancing deal, clearing debt to Elliott and paving the way for a new stadium.